Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) released its latest monthly update, confirming that public float remains at 22.22%, below the minimum threshold stipulated under Rule 19A.28B of Hong Kong’s Listing Rules.

To resolve the shortfall, the company is executing an H-Share Full Circulation plan approved on 22 December 2025. Key milestones to date include: • Filing of the conversion application with the China Securities Regulatory Commission (CSRC) on 23 December 2025. • Receipt of the CSRC filing notice on 2 April 2026, covering the conversion of 136.30 million unlisted shares held by 12 shareholders into H-shares.

Following listing approval from the Hong Kong Stock Exchange and assuming no other core-shareholder changes, Jiuyuan Gene projects that public float will rise to 31.13%, restoring compliance within the second quarter of 2026.

To prevent future breaches, the board has reinforced internal controls by: • Embedding a public-float impact review into director and connected-party trading approval processes. • Conducting monthly reviews of the shareholding structure and monitoring disclosures. • Providing annual refresher training for directors on float requirements, securities dealing and interest disclosure. • Maintaining centralized records of treasury and repurchased shares with ongoing float impact assessments.

The company will continue issuing monthly progress announcements until compliance is confirmed and advises shareholders and potential investors to exercise caution when trading its shares.